Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
A. Zanchetti.
Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?.
J Hypertens, (2009), 27 pp. 1509-1520
[2.]
A. Ichihara, M. Sakoda, A. Kurauchi-Mito, T. Narita, K. Kinouchi, K. Bokuda, et al.
New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren.
J Pharmacol Sci, (2010), 113 pp. 296-300
[3.]
J.B. Muhlestein, H.T. May, T.L. Bair, M.F. Prescott, B.D. Horne, R. White, et al.
Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease.
Am J Cardiol, (2010), 106 pp. 764-769
[4.]
R. Fogari, A. Zoppi.
New class of agents for treatment of hypertension: focus on direct renin inhibition.
Vasc Health Risk Manag, (2010), 6 pp. 869-882
[5.]
R. Pinto, A.H. Gradman.
Direct renin inhibition: an update.
Curr Hypertens Rep, (2009), 11 pp. 456-462
[6.]
G. Reboldi, G. Gentile, F. Angeli, P. Verdecchia.
Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment.
Expert Opin Drug Metab Toxicol, (2011), 7 pp. 115-128
[7.]
G. Riccioni.
Aliskiren in the treatment of hypertension and organ damage.
Cardiovasc Ther, (2011), 29 pp. 77-87
[8.]
G. Riccioni, N. Vitulano, A. Zanasi, F. Bellocci, N. D’Orazio, Aliskiren:.
beyond blood pressure reduction.
Expert Opin Investig Drugs, (2010), 19 pp. 1265-1274
[9.]
G. Nguyen.
Renin, (pro)renin and receptor: an update.
Clin Sci (Lond), (2011), 120 pp. 169-178
[10.]
P.S. Sever, A.H. Gradman, M. Azizi.
Managing cardiovascular and renal risk: the potential of direct renin inhibition.
J Renin Angiotensin Aldosterone Syst, (2009), 10 pp. 65-76
Copyright ©
2011. Sociedad Española de Cardiología